All In Biotech

Drug Trial Radar · NCT07730450

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

A PHASE 4, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF A BNT162B2 RNA-BASED, VARIANT-ADAPTED VACCINE CANDIDATE AGAINST SARS-COV-2 AND EVALUATE THE CIRCULATING SARS-COV-2 SPIKE PROTEIN LEVEL IN HEALTHY PARTICIPANTS 18 THROUGH 64 YEARS OF AGE

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jul 23, 2026

Primary completion

Aug 20, 2027

Study completion Aug 20, 2027

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Pfizer
First posted
Jul 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age. This study is seeking participants who: * are medically stable * have not had a recent COVID-19 infection * have not had a recent vaccination * do not have medical conditions that increase their risk of complications from COVID-19 All participants in this study will randomly receive 1 injection into their arm of either: * BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or * Tdap vaccine which targets tetanus, diphtheria, and pertussis (whooping cough). The study team and participants will not know which injection they receive. We will evaluate safety and SARS-CoV-2 spike protein levels in people receiving each of these vaccines. Participants will be in the study for about 12 months.

Conditions

  • COVID-19 Vaccines

Interventions

  • BNT162b2 VaccineBiological

    Participants will receive a single injection containing variant-adapted BNT162b2 on Day 1.

  • Tdap VaccineBiological

    Participants will receive a single injection containing Tdap on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting local reactions or systemic eventsTime frame: From Day 1 up to 7 days after Vaccination
  2. Percentage of participants reporting adverse eventsTime frame: From Day 1 through 1 month after vaccination
  3. Percentage of participants reporting serious adverse eventsTime frame: From Day 1 through 12 months after vaccination
  4. Spike protein levelsTime frame: Up to 12 months after vaccination

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Diablo Clinical Research, LLC dba Flourish Research

    Walnut Creek, California · Recruiting

  • Palm Springs Community Health Center

    Miami Lakes, Florida · Recruiting

  • East-West Medical Research Institute

    Honolulu, Hawaii · Recruiting

  • Duke Vaccine and Trials Unit

    Durham, North Carolina · Recruiting

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.